Displaying results 1 - 10 / 23
results / page
What publication information is included in the service?
Publication name
Authors
Publication channel
Year

First-order derivative spectrophotometric method for simultaneous determination of brinzolamide and timolol maleate in ophthalmic formulation

Peer-reviewed
Open access
DOI
10.1016/j.greeac.2024.100098
Tambe, Srushti; Das, Sabya Sachi; Shahane, Kiran; Singh, Sandeep Kumar; Ruokolainen, Janne; Amin, Pu...
Green Analytical Chemistry2024

Cardiac safety of ophthalmic timolol

Peer-reviewed
DOI
10.1080/14740338.2016.1225718
Mäenpää, Jukka; Pelkonen, Olavi
Expert opinion on drug safety2016

Crystal structure of 2-methylpiperazine-1,4-diium bis(hydrogen maleate)

Peer-reviewed
Open access
DOI
10.1107/S2056989015003102
Wecharine, Intissar;Wecharine, Intissar;Wecharine, Intissar;Valkonen, Arto;Rzaigui, Mohamed;Rzaigui,...
Acta Crystallographica Section E : Structure Reports Online2015

Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits

Peer-reviewed
Open access
DOI
10.1016/j.ejps.2020.105553
Fayyaz, Anam; Ranta, Veli-Pekka; Toropainen, Elisa; Vellonen, Kati-Sisko; Valtari, Annika; Puranen, ...
European journal of pharmaceutical sciences2020

Ocular pharmacokinetics of atenolol, timolol and betaxolol cocktail: tissue exposures in the rabbit eye

Peer-reviewed
Open access
DOI
10.1016/j.ejpb.2021.06.003
Fayyaz, Anam; Vellonen, Kati-Sisko; Ranta, Veli-Pekka; Toropainen, Elisa; Reinisalo, Mika; Valtari, ...
European journal of pharmaceutics and biopharmaceutics2021

A 6-Month Study Comparing Efficacy, Safety, and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% versus Each of Its Individual Preservative-Free Components

Peer-reviewed
Open access
DOI
10.1007/s12325-014-0163-3
Pfeiffer, Norbert; Traverso, Carlo E.; Lorenz, Katrin; Saarela, Ville; Liinamaa, Johanna; Uusitalo, ...
Advances in therapy2014

Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study

Peer-reviewed
Open access
DOI
10.1136/bmjopen-2018-024129
Bourne, RRA; Kaarniranta, K; Lorenz, K; Traverso, CE; Vuorinen, J; Ropo, A
BMJ open2019

Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study

Peer-reviewed
Open access
Bourne RR; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
Bmj Open2019

"Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops"

Peer-reviewed
DOI
10.1124/dmd.114.059576
Maenpaa, Jukka; Volotinen-Maja, Marjo; Kautiainen, Hannu; Neuvonen, Mikko; Niemi, Mikko; Neuvonen, P...
Drug metabolism and disposition2014

Metabolism of Ophthalmic Timolol: New Aspects of an Old Drug

Peer-reviewed
DOI
10.1111/j.1742-7843.2011.00694.x
Volotinen, Marjo; Hakkola, Jukka; Pelkonen, Olavi; Vapaatalo, Heikki; Maenpaa, Jukka
Basic and clinical pharmacology and toxicology2011

First-order derivative spectrophotometric method for simultaneous determination of brinzolamide and timolol maleate in ophthalmic formulation

Peer-reviewed
Open access
DOI
10.1016/j.greeac.2024.100098
2024

Cardiac safety of ophthalmic timolol

Peer-reviewed
DOI
10.1080/14740338.2016.1225718
2016

Crystal structure of 2-methylpiperazine-1,4-diium bis(hydrogen maleate)

Peer-reviewed
Open access
DOI
10.1107/S2056989015003102
2015

Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits

Peer-reviewed
Open access
DOI
10.1016/j.ejps.2020.105553
2020

Ocular pharmacokinetics of atenolol, timolol and betaxolol cocktail: tissue exposures in the rabbit eye

Peer-reviewed
Open access
DOI
10.1016/j.ejpb.2021.06.003
2021

A 6-Month Study Comparing Efficacy, Safety, and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% versus Each of Its Individual Preservative-Free Components

Peer-reviewed
Open access
DOI
10.1007/s12325-014-0163-3
2014

Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study

Peer-reviewed
Open access
DOI
10.1136/bmjopen-2018-024129
2019

Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study

Peer-reviewed
Open access
2019

"Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops"

Peer-reviewed
DOI
10.1124/dmd.114.059576
2014

Metabolism of Ophthalmic Timolol: New Aspects of an Old Drug

Peer-reviewed
DOI
10.1111/j.1742-7843.2011.00694.x
2011